OK Biotech Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for OK Biotech.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth	21.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

OK Biotech Co., Ltd. (TPE:4155) Investors Should Think About This Before Buying It For Its Dividend

Apr 26

Is OK Biotech Co., Ltd.'s (TPE:4155) Recent Price Movement Underpinned By Its Weak Fundamentals?

Feb 15

A Look At OK Biotech's (TPE:4155) Share Price Returns

Jan 31

We Wouldn't Rely On OK Biotech's (TPE:4155) Statutory Earnings As A Guide

Jan 17

Consider This Before Buying OK Biotech Co., Ltd. (TPE:4155) For The 5.4% Dividend

Jan 03

Estimating The Intrinsic Value Of OK Biotech Co., Ltd. (TPE:4155)

Dec 21

Here's Why OK Biotech (TPE:4155) Can Manage Its Debt Responsibly

Dec 08

Should You Be Impressed By OK Biotech's (TPE:4155) Returns on Capital?

Nov 23

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OK Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TWSE:4155 - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	1,192	3	-434	3	N/A
9/30/2023	1,238	29	-227	144	N/A
6/30/2023	1,271	74	-390	196	N/A
3/31/2023	1,387	113	-359	236	N/A
12/31/2022	1,484	143	-54	241	N/A
9/30/2022	1,519	147	-72	210	N/A
6/30/2022	1,520	116	45	129	N/A
3/31/2022	1,385	62	-14	63	N/A
12/31/2021	1,263	43	-65	22	N/A
9/30/2021	1,358	81	-124	27	N/A
6/30/2021	1,391	92	-44	43	N/A
3/31/2021	1,410	113	8	108	N/A
12/31/2020	1,484	130	68	148	N/A
9/30/2020	1,407	127	-33	45	N/A
6/30/2020	1,356	139	-11	112	N/A
3/31/2020	1,330	143	-117	-7	N/A
12/31/2019	1,241	126	-32	82	N/A
9/30/2019	1,169	133	36	87	N/A
6/30/2019	1,145	144	-48	0	N/A
3/31/2019	1,107	148	65	90	N/A
12/31/2018	1,120	161	77	105	N/A
9/30/2018	1,075	148	57	107	N/A
6/30/2018	1,157	139	88	148	N/A
3/31/2018	1,239	143	75	153	N/A
12/31/2017	1,233	127	10	98	N/A
9/30/2017	1,281	116	N/A	123	N/A
6/30/2017	1,182	80	N/A	155	N/A
3/31/2017	1,092	74	N/A	149	N/A
12/31/2016	1,040	85	N/A	261	N/A
9/30/2016	964	97	N/A	253	N/A
6/30/2016	942	123	N/A	272	N/A
3/31/2016	894	122	N/A	338	N/A
12/31/2015	857	111	N/A	289	N/A
9/30/2015	758	97	N/A	N/A	N/A
6/30/2015	660	83	N/A	237	N/A
3/31/2015	647	77	N/A	102	N/A
12/31/2014	634	71	N/A	-34	N/A
9/30/2014	784	84	N/A	N/A	N/A
6/30/2014	934	96	N/A	-79	N/A
3/31/2014	1,004	117	N/A	4	N/A
12/31/2013	1,074	138	N/A	87	N/A
9/30/2013	969	135	N/A	102	N/A
6/30/2013	864	132	N/A	117	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 4155's forecast earnings growth is above the savings rate (1%).

Earnings vs Market: Insufficient data to determine if 4155's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 4155's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 4155's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 4155's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4155's Return on Equity is forecast to be high in 3 years time

OK Biotech Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Full year 2023 earnings released: EPS: NT$0.02 (vs NT$1.37 in FY 2022)

OK Biotech Co., Ltd., Annual General Meeting, May 29, 2024

New minor risk - Profit margin trend

New minor risk - Market cap size

Upcoming dividend of NT$1.23 per share at 3.8% yield

Second quarter 2023 earnings released: EPS: NT$0.13 (vs NT$0.57 in 2Q 2022)

New major risk - Dividend sustainability

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: NT$1.51 (vs NT$0.46 in FY 2021)

Third quarter 2022 earnings released: EPS: NT$0.49 (vs NT$0.16 in 3Q 2021)

Less than half of directors are independent

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: NT$0.57 (vs NT$0.002 loss in 2Q 2021)

Upcoming dividend of NT$1.00 per share

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Now 21% undervalued after recent price drop

Third quarter 2021 earnings released: EPS NT$0.16 (vs NT$0.30 in 3Q 2020)

Second quarter 2021 earnings released: NT$0.002 loss per share (vs NT$0.27 profit in 2Q 2020)

Upcoming dividend of NT$1.39 per share

First quarter 2021 earnings released: EPS NT$0.32 (vs NT$0.61 in 1Q 2020)

OK Biotech Co., Ltd. (TPE:4155) Investors Should Think About This Before Buying It For Its Dividend

Calculating The Fair Value Of OK Biotech Co., Ltd. (TPE:4155)

Full year 2020 earnings released: EPS NT$1.56 (vs NT$1.71 in FY 2019)

OK Biotech (TPE:4155) Has A Pretty Healthy Balance Sheet

OK Biotech Co., Ltd., Annual General Meeting, May 27, 2021

Has OK Biotech (TPE:4155) Got What It Takes To Become A Multi-Bagger?

Is OK Biotech Co., Ltd.'s (TPE:4155) Recent Price Movement Underpinned By Its Weak Fundamentals?

A Look At OK Biotech's (TPE:4155) Share Price Returns

We Wouldn't Rely On OK Biotech's (TPE:4155) Statutory Earnings As A Guide

New 90-day low: NT$26.45

Consider This Before Buying OK Biotech Co., Ltd. (TPE:4155) For The 5.4% Dividend

New 90-day low: NT$26.55

Estimating The Intrinsic Value Of OK Biotech Co., Ltd. (TPE:4155)

New 90-day low: NT$27.85

Here's Why OK Biotech (TPE:4155) Can Manage Its Debt Responsibly

Should You Be Impressed By OK Biotech's (TPE:4155) Returns on Capital?

Third quarter 2020 earnings released: EPS NT$0.30

Revenue and earnings miss expectations

New 90-day high: NT$31.70

New 90-day low - NT$26.05

First half earnings released

OK Biotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of TWD 34.268 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies